RxDoctor Payments Data

Saad Amin, MD

Internal Medicine · Asheboro, NCNPI 1720046147

Payments from drug & device makers

$8,806in general payments, 2019–2025

Across 531 payments — averaging $16.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$989
  • AbbVie$907
  • Lilly USA, LLC$794
  • Amgen$386
  • Bayer$355
  • plus $4K from 50 others

What the payments were for

  • Food & beverage$8,806100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)56$1,046
Novo Nordisk65$989
AbbVie(2 entities)57$907
Lilly USA, LLC45$794
Amgen24$386
Bayer23$355
Sunovion Pharmaceuticals Inc.28$338
Sanofi-aventis U.S. LLC20$320
Novartis22$291
Pfizer17$280
Merck13$247
Avanir Pharmaceuticals, Inc.12$215
GSK11$207
Arbor Pharmaceuticals, Inc.8$156
Eisai Inc.9$155
Amarin Pharma, Inc.9$134
Boehringer Ingelheim6$110
Esperion Therapeutics, Inc.6$106
Corium, LLC5$87
Vifor Pharma, Inc.3$87
Xeris Pharmaceuticals, Inc.5$82
Lundbeck LLC4$82
Biogen5$80
Otsuka America Pharmaceutical, Inc.5$75
Biohaven Pharmaceuticals, Inc.3$75
Takeda Pharmaceuticals U.S.A., Inc.5$74
Sumitomo Pharma America, Inc.4$74
Johnson & Johnson6$73
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$69
Kowa Pharmaceuticals America, Inc.5$67
Teva Pharmaceuticals USA, Inc.4$65
Biohaven Pharmaceutical Holding Company Ltd.3$62
Vanda Pharmaceuticals Inc.3$60
Idorsia Pharmaceuticals US Inc3$56
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$54
Ironwood Pharmaceuticals, Inc3$49
La Jolla Pharmaceutical Company2$45
Kiniksa Pharmaceuticals International, PLC2$42
Daiichi Sankyo Inc.2$42
Nestle Healthcare Nutrition Inc.2$39
Abbott2$39
Shield Therapeutics Inc2$34
Neurocrine Biosciences, Inc.1$27
Astellas Pharma US Inc2$27
Ardelyx, Inc.1$25
Alkermes, Inc.1$23
Ultragenyx Pharmaceutical Inc.1$20
Mylan Specialty L.p.1$18
Collegium Pharmaceutical, Inc.1$17
Scilex Pharmaceuticals Inc.1$16
Edwards Lifesciences1$16
Exact Sciences1$15
CMP Pharma, Inc.1$14
Genentech USA, Inc.1$14
Biodelivery Sciences International, Inc.1$14
Dexcom, Inc.1$13

How this compares

$8,806 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$105,773
Medicare patients
210
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban259$159,546
OzempicSemaglutide107$117,692
TrulicityDulaglutide82$112,933
JardianceEmpagliflozin123$93,917
FarxigaDapagliflozin Propanediol102$86,597
LinzessLinaclotide79$47,518
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$44,161
Breztri AerosphereBudesonide/Glycopyr/Formoterol64$41,139
Repatha SureclickEvolocumab58$36,867
XareltoRivaroxaban55$35,345
CreonLipase/Protease/Amylase20$29,878
EntrestoSacubitril/Valsartan38$27,957
JanuviaSitagliptin Phosphate39$26,085
Synjardy XrEmpagliflozin/Metformin Hcl22$23,732
MounjaroTirzepatide20$21,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$280$159,546259 claims
Novo NordiskOzempic, Xultophy 100-3.6, Novolog$989$137,682133 claims
Lilly USA, LLCTrulicity, Mounjaro$794$134,681102 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,046$131,580182 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$110$125,821161 claims
AbbVieLinzess, Creon, Lumigan$907$82,311117 claims
GSKTrelegy Ellipta, Breo Ellipta$207$52,71077 claims
Johnson & JohnsonXarelto$73$35,34555 claims
NovartisEntresto$291$27,95738 claims
MerckJanuvia$247$26,08539 claims
Otsuka America Pharmaceutical, Inc.Rexulti$75$14,30111 claims
Astellas Pharma US IncMyrbetriq$27$13,73934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Asheboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →